16
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Changes in tissue prostatic acidic phosphatase during endocrine treatment of patients with prostatic carcinoma

, , , & , PhD , MD
Pages 393-398 | Received 23 Dec 2004, Published online: 09 Jul 2009

References

  • Huggins C, Hodges V. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatase in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293–7
  • Wang MC, Valenzuela LA, Murphy GP, Chu TM. Prostate antigen—a new potential marker for prostatic cancer. Prostate 1979; 2: 89–96
  • Simon HB, Nygaard KK. Clinical interpretation of total serum and “prostatic” acid phosphatase level. JAMA 1959; 171: 125–9
  • Bunting PS. Is there still a role for prostatic acid phosphatase? CSCC position statement. Clin Biochem 1999; 32: 591–4
  • Hasenson M, Lundh B, Stege R, Carlström K, Pousette Å. PAP and PSA in prostatic carcinoma cell lines and aspiration biopsies: relation to hormone sensitivity and to cytological grading. Prostate 1989; 14: 83–90
  • Stege R, Lundh B, Tribukait B, Pousette Å, Carlström K, Hasenson M. Deoxyribonucleic acid ploidy and the direct assay of prostatic acid phosphatase and prostate specific antigen in fine needle aspiration biopsies as diagnostic methods in prostatic carcinoma. J Urol 1990; 144: 299–302
  • Stege R, Tribukait B, Lundh B, Carlström K, Pousette Å, Hasenson M. Quantitative estimation of tissue prostate specific antigen, deoxyribonucleic acid ploidy and cytological grade in fine needle aspiration biopsies for prognosis of hormonally treated prostatic carcinoma. J Urol 1992; 148: 833–7
  • Labrie F, Dupont A, Belanger A, St-Arnaud R, Giguére M, Acourciére Y, et al. Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocr Rev 1986; 7: 67–74
  • Carlström K, Stege R, Henriksson P, Grande M, Gunnarsson PO, Pousette Å. Possible bone-preserving capacity of high dose intramuscular depot estrogen as compared to orchidectomy in the treatment of patients with prostatic carcinoma. Prostate 1997; 31: 193–7
  • Henttu P, Liao SS, Vihko P. Androgens up-regulate the human prostate-specific antigen messenger ribonucleic acid (mRNA) but down regulate the prostate acid phosphatase mRNA in the LNCaP cell line. J Clin Endocrinol Metab 1992; 130: 766–72
  • Henttu P, Vihko P. Steroids inversely affect the biosynthesis and secretion of human prostatic acid phosphatase and prostate-specific antigen in the LNCaP cell line. J Steroid Biochem Mol Biol 1992; 41: 349–60
  • Grande M, Carlström K, Lundh Rozell B, Stege R, Pousette Å. Prognostic value of serial tissue prostate-specific antigen measurements during different hormonal treatments in prostate cancer patients. Clin Cancer Res 2000; 6: 1790–5
  • Stege R, Grande M, Carlström K, Tribukait B, Pousette Å. Prognostic significance of tissue prostate-specific antigen in endocrine treated prostate carcinomas. Clin Cancer Res 2000; 6: 160–5
  • Frick J, Jungwirth A, Rovan E. Androgens and the prostate. Testosterone. Action, deficiency, substitution2nd ed, E Nieschlag, HM Behre. Springer, BerlinGermany 1998; 259–91

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.